Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A known ✓ | Q03164 | 1/20 | 0.46 |
| ▸ | DPP4 known ✓ | P27487 | 2/20 | 0.35 |
| ▸ | GABRP | O00591 | 2/20 | 0.52 |
| ▸ | GABRD | O14764 | 2/20 | 0.52 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.52 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.52 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.52 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.52 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.52 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.52 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.52 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.52 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.52 |
| ▸ | GABRE | P78334 | 2/20 | 0.52 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.52 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.52 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.52 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL138088 | 1.00 | GABRP (0.52) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Bicarbonate SCHEMBL4001353 | 0.84 | — | — | |
| Maleic Acid SCHEMBL8957408 | 0.81 | GABRP (0.65) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Fumaric Acid SCHEMBL21145282 | 0.81 | GABRP (0.65) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Fumaric Acid SCHEMBL21145284 | 0.81 | GABRP (0.65) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Maleic Acid SCHEMBL3118041 | 0.78 | GABRP (0.62) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Fumaric Acid SCHEMBL1835364 | 0.78 | GABRP (0.62) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Fumaric Acid SCHEMBL1835366 | 0.78 | GABRP (0.62) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Formic Acid SCHEMBL20504179 | 0.76 | — | — | |
| Formic Acid SCHEMBL20504180 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2760 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025133663-A1 | DIGITAL TISSUE REPAIR MODEL | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-06-26 | — | — | WO | claimed |
| CN-119074707-A | Research and application of alkaloid compound in prevention and treatment of abdominal aortic aneurysm | 上海市第十人民医院 | 2024-12-06 | — | — | CN | claimed |
| CN-117045628-A | Research and application of alkaloid compound in prevention and treatment of abdominal aortic aneurysm | 上海市第十人民医院 | 2023-11-14 | — | — | CN | claimed |
| US-8114152-B2 | Stent coating | ICON INTERVENTIONAL SYSTEMS, INC. (US) | 2012-02-14 | — | — | US | claimed |
| US-20090062904-A1 | STENT COATING | ICON INTERVENTIONAL SYSTEMS, INC. | 2009-03-05 | — | — | US | claimed |
| EP-1738759-A1 | Inhibition of abnormal cell proliferation with camptothecin and combinations including the same | SuperGen, Inc. (US) | 2007-01-03 | — | — | EP | claimed |
| US-20050118180-A1 | Inhibition of abnormal cell proliferation with camptothecin and combinations including the same | SUPERGEN, INC. | 2005-06-02 | — | — | US | claimed |
| EP-1276479-A2 | INHIBITION OF ABNORMAL CELL PROLIFERATION WITH CAMPTOTHECIN AND COMBINATIONS INCLUDING THE SAME | SuperGen, Inc. (US) | 2003-01-22 | — | — | EP | claimed |
| US-20020111362-A1 | Inhibition of abnormal cell proliferation with camptothecin and combinations including the same | SUPERGEN, INC. | 2002-08-15 | — | — | US | claimed |
| WO-2001080843-A2 | INHIBITION OF ABNORMAL CELL PROLIFERATION WITH CAMPTOTHECIN AND COMBINATIONS INCLUDING THE SAME | SUPERGEN, INC. (US) | 2001-11-01 | — | — | WO | claimed |
| EP-0564722-A1 | Lathyrogenic agents and apparatus for the treatment of fibrotic lesions | LATHROTEC INC (US) | 1993-10-13 | — | — | EP | claimed |
| US-5120322-A | Method and apparatus for treatment of fibrotic lesions | LATHROTEC, INC. (US) | 1992-06-09 | — | — | US | claimed |
| EP-3325513-B1 | ANTI-PD-L1 ANTIBODIES AND USES THEREOF | I MAB BIOPHARMA CO LTD (CN) | 2026-05-20 | — | — | EP | disclosed |
| US-20260130893-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4735445-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735453-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-4820843-A | Tetrazole intermediates to antihypertensive compounds | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-04-11 | — | — | US | disclosed |
| EP-0291969-A2 | Tetrazole intermediates to antihypertensive compounds | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-11-23 | — | — | EP | disclosed |
| US-4485088-A | INHIBITION OF ABNORMAL SCAR FORMATION | BIO-PRODUCTS, INC. (US) | 1984-11-27 | — | — | US | disclosed |
| US-4485088-A | INHIBITION OF ABNORMAL SCAR FORMATION | BIO-PRODUCTS, INC. (US) | 1984-11-27 | — | — | US | disclosed |